We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson Turns to Branded Drugs, Biosimilars to Drive Future Growth
Watson Turns to Branded Drugs, Biosimilars to Drive Future Growth
January 17, 2012
Hearing CEO Paul Bisaro talk about the future of Watson Pharmaceuticals, you might not realize his company is the third largest generic-drug maker in the U.S.